17 June 2024
: Case report 
Bartter Syndrome Presenting as Arginine-Vasopressin Resistance: A Report of 2 Cases
Challenging differential diagnosis, Congenital defects / diseases
Maria Sousa
1ABCDEF*, Regina Medeiros 2ABCDEF, Ana Luísa Rodrigues1ABCDEF, Bernardo Dias Pereira 2ABCDEF
DOI: 10.12659/AJCR.942872
Am J Case Rep 2024; 25:e942872
Table 1. Biochemical results of patients before and after indomethacin therapy.
| Case 1 | Case 2 | Reference [5] | |||
|---|---|---|---|---|---|
| Indomethacin | Indomethacin | ||||
| Before | After | Before | After | ||
| Sodium (mmol/L) | 153 | 143 | 140 | 145 | 138–145 |
| Chloride (mmol/L) | 109 | 104 | 104 | 106 | 98–106 |
| Calcium (mg/dL) | 10.9 | 9.1 | 8.9 | 9.0 | 8.8–10.8 |
| Potassium (mmol/L) | 3.2 | 4.1 | 3.32 | 3.34 | 3.4–4.7 |
| Magnesium (mEq/L) | 2.9 | 2.2 | 2.1 | 2.0 | 1.5–2.3 |
| Phosphorus (mg/dL) | 6.3 | 7.1 | 5.6 | 4.7 | 3.6–6.5 |
| pH | 7.56 | 7.42 | 7.38 | – | 7.35–7.43 |
| Bicarbonate (mEq/L) | 26.1 | 24.7 | 28.3 | – | 16–24 |
| Aldosterone (ng/dL) | 382.5 | 67.1 | 142.9 | 27.3 | 5–90 |
| Renin (UIU/mL) | 2469 | 485.7 | 213.2 | 67.2 | 4–89 |
| PRA (ng/mL/h) | 41.67 | 40.48 | 19.27 | 5.6 | |
| IGF1 (ng/mL) | 39.1 | – | 90.1 | – | |
| PTH (pg/mL) | 90.3 | 40.2 | 63.1 | 121.7 | 9–65 |
| Serum osmolality (mOsm/Kg HO) | 325.3 | 307.6 | 299.5 | 310.9 | 275–295 |
| Urine osmolality (mOsm/Kg HO) | 64.4 | 78.5 | 137.8 | 252 | 50–600 |
| Urinary calcium (mg/24 h) | 388 | 200 | 400 | – | 100–300 |
| Urinary chloride (mmol/24 h) | 9.3 | 7.2 | 147.7 | – | |
| FE1 of chloride (%) | 0.83 | 0.47 | 1.4 | 0.75 | <0.5 |
| FE – fractional excretion; IGF1 – insulin-like growth factor 1; PRA – plasma renin activity; PTH – parathyroid hormone. ** Reference for age of PRA (ng/mL/h): 0–3 years: *** reference for age of IGF1 (ng/mL): 6 months to 1 year: 12–104; 6 years: 37–184; **** reference for age of urinary chloride (mmol/24h): 6 months to 1 year: 2–10; 6 years: 15–40. | |||||